



**KIDS-BTB016-DMF**

**Clinical Study Report**

**A Clinical Study for the Effects of  
'3X CROSS-LINK AMPOULE + MEDI  
NANOPEN-PRO' on Improving T-zone (Right  
and Left Buccal Regions, Forehead) Pore  
and Maintaining Skin Elasticity for 24 Hours**

**Date : April 3, 2020**

**Requested by : Dermafirm INC. (Korea)**

**Performed by : Korea Institute of Dermatological Sciences (Korea)**



**Korea Institute of  
Dermatological Sciences**

# CERTIFICATE FOR RELIABILITY ASSURANCE



- Title of the clinical study : A clinical study for the effects of '3X CROSS-LINK AMPOULE + MEDI NANOPEN-PRO' on improving T-zone (right and left buccal regions, forehead) pore and maintaining skin elasticity for 24 hours
- Case control No. : KIDS-BTB016-DMF

This study was conducted according to the regulations of designation as the test institution for drugs, quasi-drugs, cosmetics, and medical devices; the guidelines of the management standards for clinical drug evaluations; the guidelines of *in vivo* clinical and *in vitro* evaluation studies; the guidelines of the experimental methods for cosmetic display and advertisements; and the guidelines of the validation of functional cosmetics of the Ministry of Food and Drug Safety, Republic of Korea; the laws of the bioethics and safety of the Ministry of Health and Welfare, Republic of Korea; and the standard operation procedure of the Korea Institute of Dermatological Sciences. All procedures were investigated by the person in charge of reliability assurance.

Title of the clinical study	A clinical study for the effects of '3X CROSS-LINK AMPOULE + MEDI NANOPEN-PRO' on improving T-zone (right and left buccal regions, forehead) pore and maintaining skin elasticity for 24 hours				
Date	Step	RA inspection categories	RA inspection result	Approval date	Note
February 17, 2020	Study plan	Reporting plan	Approved	February 17, 2020	
February 25, 2020 ~ March 18, 2020	Performing clinical trial	Reporting implementation	Approved	March 18, 2020	
March 19, 2020 ~ March 25, 2020	Analyzing data, Confirming the information on test products	Inspecting raw data	Approved	March 25, 2020	
March 26, 2020 ~ April 02, 2020	Report work	Inspecting draft report	Approved	April 02, 2020	
April 03, 2020	Report final report	Inspecting final report	Approved	April 03, 2020	

This report was prepared on the basis of the experiment results and accurately reflects the data.

April 3, 2020

Scientific Director In Sook An, Ph.D. 

Reliability Assurance Jinhyuk Jung, Ph.D. 

This report is the confidential document and property of the Korea Institute of Dermatological Sciences; its transfer, plagiarism, and disclosure to third parties is prohibited.

# SUMMARY OF THE CLINICAL STUDY



Title of the clinical study	A clinical study for the effects of '3X CROSS-LINK AMPOULE + MEDI NANOPEN-PRO' on improving T-zone (right and left buccal regions, forehead) pore and maintaining skin elasticity for 24 hours	
Clinical trial institution	Korea Institute of Dermatological Sciences 6th Floor, Tower A, 25, Beobwon-ro 11-gil, Songpa-gu, Seoul, 05836, Republic of Korea	
Sponsor	Dermafirm INC.	
Chief researcher	In Sook An, Ph.D.	
Researcher	Research Director Seung Bin Kwon, Ph.D. Research Engineer Yujeong Kwon Associate Research Engineer Seulki Yoon · Min Ji Jo · Sujeong Shin Yoonmi Choi · Dasom shin · Songhee Han	
Name of the test products	3X CROSS-LINK AMPOULE (Test product A) MEDI NANOPEN-PRO (Test product B)	
Trial period	February 17, 2020 (study initiation) ~ April 3, 2020 (study termination) For the study initiation, the person in charge of the study signed the clinical study proposal; for the study termination, the person in charge of the study signed the final report.	
Subjects	Twenty-three subjects of either sex from forty to sixty years old who met the inclusion criteria and were not included in the exclusion criteria were selected for this study.	
Methods	Usage of test products	After washing face twice a day, in the morning and in the evening, during the three weeks test period, each subject applied the same amount of test product A '3X CROSS-LINK AMPOULE' evenly to face area, and only once a week, additionally applied test product B 'MEDI NANOPEN-PRO' for 10 minutes along the entire surface of the skin.
	Evaluations	The evaluations were conducted by Standard Operating Procedures of KIDS and all of the procedures were investigated by the person in charge of reliability assurance.  1. Measurements 1) Evaluation using VISIA-CA to assess the T-zone (right and left buccal regions, forehead) pore improvement

This report is the confidential document and property of the Korea Institute of Dermatological Sciences; its transfer, plagiarism, and disclosure to third parties is prohibited.

# SUMMARY OF THE CLINICAL STUDY



Methods	Evaluations	<ol style="list-style-type: none"> <li>2) Evaluation using Ballistometer to assess the maintaining skin elasticity for 24 hours</li> <li>2. Evaluation of abnormal skin response</li> <li>3. Survey</li> </ol>
Results	<ol style="list-style-type: none"> <li>1. The evaluation results of T-zone (right and left buccal regions, forehead) pore using VISIA-CA The number of pores was decreased 9.37% after three weeks of the test products application in comparison with the pre-application (<math>p &lt; .05</math>).</li> <li>2. The evaluation results of maintaining skin elasticity for 24 hours using Ballistometer The CoR value indicating skin elasticity was increased 3.26% and 2.34% after three weeks of the test products application and 24 hours after stop using the test products respectively in comparison with the pre-application (<math>p &lt; .001</math>).</li> <li>3. Subjects' abnormal skin responses were not detected during the trial period.</li> </ol>	
Conclusion	<p>In the study requested by Dermafirm INC., '3X CROSS-LINK AMPOULE + MEDI NANOPEEN-PRO' were found to improve T-zone (right and left buccal regions, forehead) pore and maintaining skin elasticity for 24 hours.</p>	

This report is the confidential document and property of the Korea Institute of Dermatological Sciences; its transfer, plagiarism, and disclosure to third parties is prohibited.